BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-374@pharmaconomics
DTSTAMP:20260707T034253Z
DTSTART;VALUE=DATE:20260520
DTEND;VALUE=DATE:20260521
SUMMARY:PVLA Phase 2 — QTORIN™ rapamycin
DESCRIPTION:Phase 2 trial results for QTORIN™ rapamycin in Clinically Significant Angiokeratomas are due May 20\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/pvla-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/374
URL:https://www.pharmaconomics.com/e/374
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PVLA catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR